Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Fosinopril
- Accession Number
- DB00492 (APRD00526)
- Type
- Small Molecule
- Groups
- Approved
- Description
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
- Structure
Structure for DB00492 (Fosinopril)
- Synonyms
- Fosenopril
- Product Ingredients
Ingredient UNII CAS InChI Key Fosinopril sodium NW2RTH6T2N 88889-14-9 TVTJZMHAIQQZTL-UHFFFAOYSA-M - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Fosinopril Tablet 10 mg Oral Sanis Health Inc 2017-04-11 Not applicable Canada 
Fosinopril Tablet 20 mg Oral Sanis Health Inc 2017-04-11 Not applicable Canada Fosinopril Tablets Tablet 20 mg Oral Ranbaxy Inc. Not applicable Not applicable Canada Fosinopril Tablets Tablet 10 mg Oral Ranbaxy Inc. Not applicable Not applicable Canada Fosinopril-10 Tablet 10 mg Oral Pro Doc Limitee 2008-10-23 Not applicable Canada Fosinopril-20 Tablet 20 mg Oral Pro Doc Limitee 2008-10-23 Not applicable Canada Monopril Tab 10mg Tablet 10 mg Oral Bristol Myers Squibb 1992-12-31 2013-06-17 Canada Monopril Tab 20mg Tablet 20 mg Oral Bristol Myers Squibb 1992-12-31 2013-06-17 Canada Ratio Fosinopril Tablet 20 mg Oral Ratiopharm Inc Division Of Teva Canada Limited 2006-02-08 2008-08-01 Canada Ratio Fosinopril Tablet 10 mg Oral Ratiopharm Inc Division Of Teva Canada Limited 2006-02-08 2008-08-01 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-fosinopril Tablet 10 mg Oral Apotex Corporation 2005-04-27 Not applicable Canada Apo-fosinopril Tablet 20 mg Oral Apotex Corporation 2005-04-27 Not applicable Canada Ava-fosinopril Tablet 20 mg Oral Avanstra Inc 2011-11-28 2014-08-21 Canada Ava-fosinopril Tablet 10 mg Oral Avanstra Inc 2011-11-28 2014-08-21 Canada FOSINOPRIL Na Tablet 10 mg/1 Oral Apotex Corporation 2005-05-18 2017-02-24 US 
FOSINOPRIL Na Tablet 40 mg/1 Oral Apotex Corporation 2005-05-18 2017-02-24 US 
FOSINOPRIL Na Tablet 20 mg/1 Oral Apotex Corporation 2005-05-18 2017-02-24 US Fosinopril Sodium Tablet 10 mg/1 Oral Physicians Total Care, Inc. 2004-05-18 Not applicable US Fosinopril Sodium Tablet 10 mg/1 Oral bryant ranch prepack 2007-09-17 Not applicable US 
Fosinopril Sodium Tablet 40 mg/1 Oral bryant ranch prepack 2016-06-16 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Glenmark Pharmaceuticals Inc.,Usa 2009-07-09 Not applicable US Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Rising Health, Llc 2009-07-09 Not applicable US Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Heritage 2011-11-15 Not applicable US Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Ranbaxy Inc. 2004-12-20 Not applicable US Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Physicians Total Care, Inc. 2005-07-06 Not applicable US Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral bryant ranch prepack 2009-07-09 Not applicable US Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Aurobindo Pharma 2009-07-09 Not applicable US Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Ranbaxy Inc. 2004-12-20 Not applicable US Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Eon Labs, Inc. 2005-09-28 Not applicable US Fosinopril Sodium and Hydrochlorothiazide Fosinopril sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1) Tablet Oral Heritage 2011-11-15 Not applicable US - International/Other Brands
- Acecor (SPA (Czech Republic)) / Monopril (Bristol-Myers Squibb) / Staril (BMS (United Kingdom))
- Categories
- ACE Inhibitors and Diuretics
- Acids
- Acids, Acyclic
- Acids, Noncarboxylic
- Agents Acting on the Renin-Angiotensin System
- Agents causing hyperkalemia
- Amino Acids
- Amino Acids, Cyclic
- Amino Acids, Peptides, and Proteins
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
- Cardiovascular Agents
- Cardiovascular System
- Enzyme Inhibitors
- Hypotensive Agents
- Imines
- Imino Acids
- Organophosphorus Compounds
- Phosphinic Acids
- Phosphorus Acids
- Phosphorus Compounds
- Proline
- Protease Inhibitors
- UNII
- R43D2573WO
- CAS number
- 98048-97-6
- Weight
- Average: 563.672
Monoisotopic: 563.301189823 - Chemical Formula
- C30H46NO7P
- InChI Key
- BIDNLKIUORFRQP-XYGFDPSESA-N
- InChI
- InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30+,39-/m1/s1
- IUPAC Name
- (2S,4S)-4-cyclohexyl-1-{2-[(R)-[(1S)-2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl]acetyl}pyrrolidine-2-carboxylic acid
- SMILES
- CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C
Pharmacology
- Indication
For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
- Associated Conditions
- Pharmacodynamics
Following oral administration, fosinopril is rapidly and completely hydrolyzed to its principle active metabolite, fosinoprilat. Hydrolysis is thought to occur in the gastrointestinal mucosa and liver. Fosinoprilat is a competitive inhibitor of ACE, a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of fosinoprilat by causing increased vasodilation and decreased blood pressure.
- Mechanism of action
There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
Target Actions Organism AAngiotensin-converting enzyme inhibitorHuman - Absorption
Average absolute absorption is 36%. The primary site of absorption is the proximal small intestine (duodenum/jejunum). Food slows the rate of absorption with no effect on the extent of absorption.
- Volume of distribution
- Not Available
- Protein binding
Fosinoprilat is ≥95% protein bound
- Metabolism
Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites.
- Route of elimination
After oral administration of radiolabeled fosinopril, approximately half of the absorbed dose is excreted in the urine and the remainder is excreted in the feces.
- Half life
12 hours
- Clearance
- 26 - 39 mL/min [healthy]
- Toxicity
Human overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality. The most common adverse effects include dizzines, cough, fatigue, and headache.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Fosinopril Metabolism Pathway Drug metabolism Fosinopril Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Acebutolol Fosinopril may increase the hypotensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Fosinopril. Approved, Investigational Acemetacin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acemetacin is combined with Fosinopril. Approved, Experimental, Investigational Acetylsalicylic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acetylsalicylic acid is combined with Fosinopril. Approved, Vet Approved Agrostis gigantea pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Agrostis gigantea pollen. Approved Agrostis stolonifera pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Agrostis stolonifera pollen. Approved Alclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alclofenac is combined with Fosinopril. Approved, Withdrawn Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril. Approved Alfuzosin Alfuzosin may increase the hypotensive activities of Fosinopril. Approved, Investigational Aliskiren The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Fosinopril. Approved, Investigational Allopurinol The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Fosinopril. Approved Almasilate Almasilate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental Alminoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alminoprofen is combined with Fosinopril. Experimental Alogliptin The risk or severity of angioedema can be increased when Alogliptin is combined with Fosinopril. Approved Aloglutamol Aloglutamol can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Aloxiprin The risk or severity of renal failure can be increased when Aloxiprin is combined with Fosinopril. Experimental Alprenolol Fosinopril may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Aluminium Aluminium can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Aluminium acetoacetate Aluminium acetoacetate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminium glycinate Aluminium glycinate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Ambrisentan Fosinopril may increase the hypotensive activities of Ambrisentan. Approved, Investigational AMG-222 The risk or severity of angioedema can be increased when AMG-222 is combined with Fosinopril. Investigational Amifostine Fosinopril may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride The risk or severity of hyperkalemia can be increased when Amiloride is combined with Fosinopril. Approved Aminophenazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Fosinopril. Approved, Withdrawn Aminosalicylic Acid The risk or severity of renal failure can be increased when Aminosalicylic Acid is combined with Fosinopril. Approved Amiodarone The risk or severity of adverse effects can be increased when Amiodarone is combined with Fosinopril. Approved, Investigational Amlodipine Amlodipine may increase the hypotensive activities of Fosinopril. Approved Amobarbital Amobarbital may increase the hypotensive activities of Fosinopril. Approved, Illicit Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Fosinopril. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Fosinopril is combined with Amyl Nitrite. Approved Anagliptin The risk or severity of angioedema can be increased when Anagliptin is combined with Fosinopril. Investigational Anisodamine The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Anisodamine. Investigational Anthoxanthum odoratum pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Anthoxanthum odoratum pollen. Approved Antipyrine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antipyrine is combined with Fosinopril. Approved, Investigational Antrafenine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antrafenine is combined with Fosinopril. Approved Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Fosinopril. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Fosinopril is combined with Apraclonidine. Approved Aprotinin Aprotinin may decrease the antihypertensive activities of Fosinopril. Approved, Investigational, Withdrawn Ardeparin The risk or severity of hyperkalemia can be increased when Ardeparin is combined with Fosinopril. Approved, Investigational, Withdrawn Aripiprazole Aripiprazole may increase the hypotensive activities of Fosinopril. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Fosinopril. Investigational Arrhenatherum elatius pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Arrhenatherum elatius pollen. Approved Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fosinopril. Approved, Investigational Atenolol Atenolol may increase the hypotensive activities of Fosinopril. Approved Avanafil Avanafil may increase the antihypertensive activities of Fosinopril. Approved Azapropazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Fosinopril. Withdrawn Azathioprine The risk or severity of anemia and severe leukopenia can be increased when Fosinopril is combined with Azathioprine. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fosinopril. Approved, Investigational Azosemide Azosemide may increase the hypotensive activities of Fosinopril. Investigational Balsalazide The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Fosinopril. Approved, Investigational Barbexaclone Barbexaclone may increase the hypotensive activities of Fosinopril. Experimental Barbital Barbital may increase the hypotensive activities of Fosinopril. Illicit Barnidipine Fosinopril may increase the antihypertensive activities of Barnidipine. Approved Befunolol The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Befunolol. Experimental Bemiparin The risk or severity of hyperkalemia can be increased when Bemiparin is combined with Fosinopril. Approved, Investigational Benazepril Fosinopril may increase the hypotensive activities of Benazepril. Approved, Investigational Benazeprilat Fosinopril may increase the hypotensive activities of Benazeprilat. Experimental Bendazac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bendazac is combined with Fosinopril. Experimental Bendroflumethiazide The risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Fosinopril. Approved Benmoxin Benmoxin may increase the hypotensive activities of Fosinopril. Withdrawn Benorilate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benorilate is combined with Fosinopril. Experimental Benoxaprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benoxaprofen is combined with Fosinopril. Withdrawn Benzthiazide The risk or severity of hypotension can be increased when Benzthiazide is combined with Fosinopril. Approved Benzydamine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benzydamine is combined with Fosinopril. Approved Bepridil Fosinopril may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betaxolol Betaxolol may increase the hypotensive activities of Fosinopril. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Fosinopril. Approved Bevantolol Fosinopril may increase the hypotensive activities of Bevantolol. Approved Bietaserpine Bietaserpine may increase the hypotensive activities of Fosinopril. Experimental Bimatoprost Fosinopril may increase the hypotensive activities of Bimatoprost. Approved, Investigational Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Bisoprolol Fosinopril may increase the hypotensive activities of Bisoprolol. Approved Bopindolol The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Bopindolol. Approved Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Fosinopril. Approved, Investigational Bosentan Bosentan may increase the hypotensive activities of Fosinopril. Approved, Investigational Bouteloua gracilis pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Bouteloua gracilis pollen. Approved BQ-123 Fosinopril may increase the hypotensive activities of BQ-123. Investigational Bretylium Fosinopril may increase the hypotensive activities of Bretylium. Approved Bromfenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bromfenac is combined with Fosinopril. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Fosinopril. Approved, Investigational Bromus secalinus pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Bromus secalinus pollen. Approved Bucindolol The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Bucindolol. Investigational Bufexamac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bufexamac is combined with Fosinopril. Approved, Experimental Bufuralol The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Bufuralol. Experimental, Investigational Bumadizone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bumadizone is combined with Fosinopril. Experimental Bumetanide Bumetanide may increase the hypotensive activities of Fosinopril. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Fosinopril. Approved, Investigational Bupranolol Fosinopril may increase the hypotensive activities of Bupranolol. Approved Cadralazine Cadralazine may increase the hypotensive activities of Fosinopril. Experimental Calcium Carbonate Calcium Carbonate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Calcium silicate Calcium silicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Canagliflozin The risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Fosinopril. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Fosinopril. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fosinopril. Approved Candoxatril Fosinopril may increase the hypotensive activities of Candoxatril. Experimental Captopril Fosinopril may increase the hypotensive activities of Captopril. Approved Carbaspirin calcium The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carbaspirin calcium is combined with Fosinopril. Experimental, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Fosinopril. Approved, Investigational Carmegliptin The risk or severity of angioedema can be increased when Carmegliptin is combined with Fosinopril. Investigational Caroxazone Caroxazone may increase the hypotensive activities of Fosinopril. Withdrawn Carprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carprofen is combined with Fosinopril. Approved, Vet Approved, Withdrawn Carteolol Fosinopril may increase the hypotensive activities of Carteolol. Approved Carvedilol Fosinopril may increase the hypotensive activities of Carvedilol. Approved, Investigational Celecoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Fosinopril. Approved, Investigational Celiprolol Fosinopril may increase the hypotensive activities of Celiprolol. Approved, Investigational Certoparin The risk or severity of hyperkalemia can be increased when Certoparin is combined with Fosinopril. Approved, Investigational Chlorothiazide The risk or severity of hypotension can be increased when Chlorothiazide is combined with Fosinopril. Approved, Vet Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fosinopril. Approved, Investigational, Vet Approved Chlorthalidone The risk or severity of hypotension can be increased when Chlorthalidone is combined with Fosinopril. Approved Choline magnesium trisalicylate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Choline magnesium trisalicylate is combined with Fosinopril. Approved Cicletanine Fosinopril may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Fosinopril may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Fosinopril. Approved, Investigational Cimicoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Cimicoxib is combined with Fosinopril. Investigational Ciprofloxacin The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Ciprofloxacin. Approved, Investigational Clevidipine The risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine. Approved, Investigational Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Fosinopril. Approved, Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Fosinopril. Approved, Investigational, Vet Approved Clonidine Clonidine may increase the hypotensive activities of Fosinopril. Approved Clonixin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Clonixin is combined with Fosinopril. Approved Cloranolol Fosinopril may increase the hypotensive activities of Cloranolol. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Fosinopril. Approved Conivaptan The risk or severity of adverse effects can be increased when Conivaptan is combined with Fosinopril. Approved, Investigational Cryptenamine Fosinopril may increase the hypotensive activities of Cryptenamine. Approved Cyclopenthiazide The risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Fosinopril. Experimental Cyclosporine The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyclothiazide Fosinopril may increase the hypotensive activities of Cyclothiazide. Approved Cynodon dactylon pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Cynodon dactylon pollen. Approved Dactylis glomerata pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Dactylis glomerata pollen. Approved Dalteparin The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Fosinopril. Approved Danaparoid The risk or severity of hyperkalemia can be increased when Danaparoid is combined with Fosinopril. Approved, Withdrawn Dapagliflozin The risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Fosinopril. Approved Dapoxetine Dapoxetine may increase the orthostatic hypotensive activities of Fosinopril. Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Fosinopril. Approved, Investigational Delapril Fosinopril may increase the hypotensive activities of Delapril. Investigational Dersalazine The risk or severity of renal failure can be increased when Dersalazine is combined with Fosinopril. Investigational Deserpidine Fosinopril may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Fosinopril. Approved Dexibuprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexibuprofen is combined with Fosinopril. Approved, Investigational Dexketoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexketoprofen is combined with Fosinopril. Approved, Investigational Dexlansoprazole Dexlansoprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Dexmedetomidine The risk or severity of adverse effects can be increased when Fosinopril is combined with Dexmedetomidine. Approved, Vet Approved Dexniguldipine Fosinopril may increase the hypotensive activities of Dexniguldipine. Experimental Dexrabeprazole Dexrabeprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Diazoxide Diazoxide may increase the hypotensive activities of Fosinopril. Approved Diclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Fosinopril. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenamide. Approved, Investigational Diethylnorspermine Fosinopril may increase the hypotensive activities of Diethylnorspermine. Investigational Difenpiramide The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Difenpiramide is combined with Fosinopril. Experimental Diflunisal The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diflunisal is combined with Fosinopril. Approved, Investigational Digoxin The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Digoxin. Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Fosinopril. Approved, Investigational Diltiazem Diltiazem may increase the hypotensive activities of Fosinopril. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab. Approved, Investigational Dipyridamole Dipyridamole may increase the antihypertensive activities of Fosinopril. Approved Distichlis spicata pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Distichlis spicata pollen. Approved Dorzolamide Fosinopril may increase the hypotensive activities of Dorzolamide. Approved Doxazosin Doxazosin may increase the hypotensive activities of Fosinopril. Approved Drospirenone Fosinopril may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Fosinopril. Withdrawn Duloxetine Fosinopril may increase the orthostatic hypotensive activities of Duloxetine. Approved Dutogliptin The risk or severity of angioedema can be increased when Dutogliptin is combined with Fosinopril. Investigational Efonidipine Fosinopril may increase the hypotensive activities of Efonidipine. Approved, Investigational Elymus repens pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Elymus repens pollen. Approved Empagliflozin The risk or severity of renal failure and hyperkalemia can be increased when Empagliflozin is combined with Fosinopril. Approved Enalapril Fosinopril may increase the hypotensive activities of Enalapril. Approved, Vet Approved Enalaprilat Fosinopril may increase the hypotensive activities of Enalaprilat. Approved Endralazine Endralazine may increase the hypotensive activities of Fosinopril. Experimental Enoxaparin The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Fosinopril. Approved Epanolol Fosinopril may increase the hypotensive activities of Epanolol. Experimental Epirizole The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Epirizole is combined with Fosinopril. Approved Epitizide The risk or severity of hypotension can be increased when Epitizide is combined with Fosinopril. Experimental Eplerenone Eplerenone may increase the hyperkalemic activities of Fosinopril. Approved Epoprostenol Epoprostenol may increase the hypotensive activities of Fosinopril. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Fosinopril. Approved Ertugliflozin The risk or severity of renal failure and hyperkalemia can be increased when Ertugliflozin is combined with Fosinopril. Approved, Investigational Esatenolol Fosinopril may increase the hypotensive activities of Esatenolol. Experimental Esmolol Fosinopril may increase the hypotensive activities of Esmolol. Approved Esomeprazole Esomeprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Etacrynic acid Etacrynic acid may increase the hypotensive activities of Fosinopril. Approved, Investigational Ethenzamide The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ethenzamide is combined with Fosinopril. Experimental Etodolac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etodolac is combined with Fosinopril. Approved, Investigational, Vet Approved Etofenamate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etofenamate is combined with Fosinopril. Approved, Investigational Etoricoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Fosinopril. Approved, Investigational Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril. Approved Evogliptin The risk or severity of angioedema can be increased when Evogliptin is combined with Fosinopril. Investigational Felbinac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Felbinac is combined with Fosinopril. Experimental Felodipine Fosinopril may increase the hypotensive activities of Felodipine. Approved, Investigational Fenbufen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenbufen is combined with Fosinopril. Approved Fenoldopam Fosinopril may increase the hypotensive activities of Fenoldopam. Approved Fenoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Fosinopril. Approved Fentiazac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fentiazac is combined with Fosinopril. Experimental Feprazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Feprazone is combined with Fosinopril. Experimental Ferulic acid Fosinopril may increase the hypotensive activities of Ferulic acid. Experimental Festuca pratensis pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Festuca pratensis pollen. Approved Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Fosinopril. Approved, Investigational Firocoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Firocoxib is combined with Fosinopril. Experimental, Vet Approved Floctafenine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Floctafenine is combined with Fosinopril. Approved, Withdrawn Fluconazole The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Fluconazole. Approved, Investigational Flunixin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flunixin is combined with Fosinopril. Vet Approved Flunoxaprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flunoxaprofen is combined with Fosinopril. Experimental Flurbiprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen is combined with Fosinopril. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Fosinopril. Experimental Fosinoprilat Fosinopril may increase the hypotensive activities of Fosinoprilat. Experimental Fostamatinib Fostamatinib may increase the antihypertensive activities of Fosinopril. Approved, Investigational Furazolidone Furazolidone may increase the hypotensive activities of Fosinopril. Approved, Investigational, Vet Approved Furosemide Furosemide may increase the hypotensive activities of Fosinopril. Approved, Vet Approved Gemigliptin The risk or severity of angioedema can be increased when Gemigliptin is combined with Fosinopril. Investigational Gosogliptin The risk or severity of angioedema can be increased when Gosogliptin is combined with Fosinopril. Investigational Guacetisal The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Guacetisal is combined with Fosinopril. Experimental Guanabenz Fosinopril may increase the hypotensive activities of Guanabenz. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Fosinopril. Approved Guanazodine Fosinopril may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Fosinopril may increase the hypotensive activities of Guanethidine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Fosinopril. Approved, Investigational Guanoclor Fosinopril may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Fosinopril may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Fosinopril may increase the hypotensive activities of Guanoxan. Experimental Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Fosinopril. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Fosinopril. Experimental Heparin The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Heparin. Approved, Investigational Hexamethonium Fosinopril may increase the hypotensive activities of Hexamethonium. Experimental Hexobarbital Hexobarbital may increase the hypotensive activities of Fosinopril. Approved Holcus lanatus pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Holcus lanatus pollen. Approved Hydracarbazine Hydracarbazine may increase the hypotensive activities of Fosinopril. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Fosinopril. Approved Hydrochlorothiazide The risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Fosinopril. Approved, Vet Approved Hydroflumethiazide The risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Fosinopril. Approved, Investigational Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Experimental, Investigational Ibuprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Fosinopril. Approved Ibuproxam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuproxam is combined with Fosinopril. Withdrawn Icatibant Icatibant may decrease the antihypertensive activities of Fosinopril. Approved, Investigational Icosapent The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Icosapent is combined with Fosinopril. Approved, Nutraceutical Iloprost Iloprost may increase the hypotensive activities of Fosinopril. Approved, Investigational Imidapril Fosinopril may increase the hypotensive activities of Imidapril. Investigational Imidazole salicylate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Imidazole salicylate is combined with Fosinopril. Experimental Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Fosinopril. Approved Indapamide The risk or severity of hypotension can be increased when Indapamide is combined with Fosinopril. Approved Indenolol Fosinopril may increase the hypotensive activities of Indenolol. Withdrawn Indobufen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indobufen is combined with Fosinopril. Investigational Indomethacin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Fosinopril. Approved, Investigational Indoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indoprofen is combined with Fosinopril. Withdrawn Indoramin Indoramin may increase the hypotensive activities of Fosinopril. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Fosinopril. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Fosinopril. Approved, Investigational Iron Iron can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Iron Dextran The risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran. Approved, Vet Approved Isocarboxazid Isocarboxazid may increase the hypotensive activities of Fosinopril. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Fosinopril. Approved, Vet Approved Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Mononitrate. Approved Isoxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Isoxicam is combined with Fosinopril. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Fosinopril is combined with Isoxsuprine. Approved, Withdrawn Isradipine Isradipine may increase the hypotensive activities of Fosinopril. Approved, Investigational Itraconazole The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Itraconazole. Approved, Investigational Kebuzone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Kebuzone is combined with Fosinopril. Experimental Ketanserin Ketanserin may increase the hypotensive activities of Fosinopril. Investigational Ketoconazole The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Fosinopril. Approved, Vet Approved Ketorolac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Fosinopril. Approved Koeleria macrantha pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Koeleria macrantha pollen. Approved KRP-104 The risk or severity of angioedema can be increased when KRP-104 is combined with Fosinopril. Investigational Labetalol Fosinopril may increase the hypotensive activities of Labetalol. Approved Lacidipine Fosinopril may increase the hypotensive activities of Lacidipine. Approved, Investigational Landiolol The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Landiolol. Investigational Lansoprazole Lansoprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Lanthanum carbonate The serum concentration of Fosinopril can be decreased when it is combined with Lanthanum carbonate. Approved Latanoprost Fosinopril may increase the hypotensive activities of Latanoprost. Approved, Investigational Lercanidipine Fosinopril may increase the hypotensive activities of Lercanidipine. Approved, Investigational Levobetaxolol The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Levobetaxolol. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Fosinopril is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fosinopril. Approved, Investigational Levodopa Fosinopril may increase the orthostatic hypotensive activities of Levodopa. Approved Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Fosinopril. Approved, Investigational Linagliptin The risk or severity of angioedema can be increased when Linagliptin is combined with Fosinopril. Approved Linezolid Linezolid may increase the hypotensive activities of Fosinopril. Approved, Investigational Linsidomine Fosinopril may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Fosinopril may increase the hypotensive activities of Lisinopril. Approved, Investigational Lithium cation The serum concentration of Lithium cation can be increased when it is combined with Fosinopril. Experimental Lofexidine Fosinopril may increase the hypotensive activities of Lofexidine. Approved, Investigational Lolium perenne pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Lolium perenne pollen. Approved Lolium perenne subsp. multiflorum pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Lolium perenne subsp. multiflorum pollen. Approved Lonazolac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lonazolac is combined with Fosinopril. Experimental Lornoxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Fosinopril. Approved, Investigational Losartan The risk or severity of adverse effects can be increased when Losartan is combined with Fosinopril. Approved Loxoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Loxoprofen is combined with Fosinopril. Approved, Investigational Lumiracoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lumiracoxib is combined with Fosinopril. Approved, Investigational Macitentan Fosinopril may increase the hypotensive activities of Macitentan. Approved Magaldrate Magaldrate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Withdrawn Magnesium carbonate Magnesium carbonate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium peroxide Magnesium peroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Magnesium salicylate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Fosinopril. Approved Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Magnesium Trisilicate Magnesium Trisilicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Manidipine Fosinopril may increase the hypotensive activities of Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Fosinopril is combined with Mannitol. Approved, Investigational Mannitol busulfan The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Mannitol busulfan. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Fosinopril. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Fosinopril. Approved, Investigational Meclofenamic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Fosinopril. Approved, Vet Approved Mefenamic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Fosinopril. Approved Meloxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meloxicam is combined with Fosinopril. Approved, Vet Approved Mepindolol The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Mepindolol. Experimental Mesalazine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Fosinopril. Approved Metamizole The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Metamizole is combined with Fosinopril. Approved, Investigational, Withdrawn Methazolamide The risk or severity of adverse effects can be increased when Fosinopril is combined with Methazolamide. Approved Methohexital Methohexital may increase the hypotensive activities of Fosinopril. Approved Methoserpidine Fosinopril may increase the hypotensive activities of Methoserpidine. Experimental Methyclothiazide The risk or severity of hypotension can be increased when Methyclothiazide is combined with Fosinopril. Approved Methyl salicylate The risk or severity of renal failure can be increased when Methyl salicylate is combined with Fosinopril. Approved, Vet Approved Methyldopa Fosinopril may increase the hypotensive activities of Methyldopa. Approved Methylene blue Methylene blue may increase the hypotensive activities of Fosinopril. Approved, Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Fosinopril. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the hypotensive activities of Fosinopril. Approved Metipranolol Fosinopril may increase the hypotensive activities of Metipranolol. Approved Metolazone The risk or severity of hypotension can be increased when Metolazone is combined with Fosinopril. Approved Metoprolol Metoprolol may increase the hypotensive activities of Fosinopril. Approved, Investigational Metyrosine Fosinopril may increase the hypotensive activities of Metyrosine. Approved Mibefradil Fosinopril may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Minaprine Minaprine may increase the hypotensive activities of Fosinopril. Approved Minoxidil Minoxidil may increase the hypotensive activities of Fosinopril. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Fosinopril. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Fosinopril. Approved, Investigational Moexipril Fosinopril may increase the hypotensive activities of Moexipril. Approved Mofebutazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mofebutazone is combined with Fosinopril. Experimental Molsidomine Molsidomine may increase the hypotensive activities of Fosinopril. Approved, Investigational Morniflumate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Morniflumate is combined with Fosinopril. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Fosinopril. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Fosinopril. Approved, Investigational Muzolimine Fosinopril may increase the hypotensive activities of Muzolimine. Experimental Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Fosinopril. Approved, Investigational Nabumetone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Fosinopril. Approved Nadolol Fosinopril may increase the hypotensive activities of Nadolol. Approved Nadroparin The risk or severity of hyperkalemia can be increased when Nadroparin is combined with Fosinopril. Approved, Investigational Naftopidil Fosinopril may increase the hypotensive activities of Naftopidil. Investigational Naproxen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Fosinopril. Approved, Vet Approved Nebivolol Fosinopril may increase the hypotensive activities of Nebivolol. Approved, Investigational Nepafenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nepafenac is combined with Fosinopril. Approved, Investigational Nesiritide The risk or severity of adverse effects can be increased when Fosinopril is combined with Nesiritide. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Fosinopril. Withdrawn Nicardipine Fosinopril may increase the hypotensive activities of Nicardipine. Approved, Investigational Nicorandil Nicorandil may increase the vasodilatory activities of Fosinopril. Approved, Investigational Nifedipine The risk or severity of adverse effects can be increased when Fosinopril is combined with Nifedipine. Approved Nifenazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nifenazone is combined with Fosinopril. Experimental Niflumic Acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Niflumic Acid is combined with Fosinopril. Approved Niguldipine Fosinopril may increase the hypotensive activities of Niguldipine. Experimental Nilvadipine Fosinopril may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimesulide The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Fosinopril. Approved, Investigational, Withdrawn Nimodipine Nimodipine may increase the hypotensive activities of Fosinopril. Approved, Investigational Nisoldipine Nisoldipine may increase the hypotensive activities of Fosinopril. Approved Nitrendipine Fosinopril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Fosinopril. Approved Nitroaspirin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nitroaspirin is combined with Fosinopril. Investigational Nitroglycerin The risk or severity of adverse effects can be increased when Fosinopril is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Fosinopril. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Nitrous acid is combined with Fosinopril. Approved, Investigational NS-398 The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when NS-398 is combined with Fosinopril. Experimental Obinutuzumab Fosinopril may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Fosinopril. Withdrawn Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Fosinopril. Approved, Investigational Olsalazine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olsalazine is combined with Fosinopril. Approved Omapatrilat Fosinopril may increase the hypotensive activities of Omapatrilat. Investigational Omarigliptin The risk or severity of angioedema can be increased when Omarigliptin is combined with Fosinopril. Investigational Omeprazole Omeprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational, Vet Approved Oxaprozin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxaprozin is combined with Fosinopril. Approved Oxprenolol Fosinopril may increase the hypotensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Fosinopril. Approved, Withdrawn Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Fosinopril. Approved, Vet Approved Pantoprazole Pantoprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Papaverine The risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine. Approved, Investigational Parecoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with Fosinopril. Approved Pargyline Pargyline may increase the hypotensive activities of Fosinopril. Approved Parnaparin The risk or severity of hyperkalemia can be increased when Parnaparin is combined with Fosinopril. Approved, Investigational Pascopyrum smithii pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Pascopyrum smithii pollen. Approved Paspalum notatum pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Paspalum notatum pollen. Approved Patent Blue The risk or severity of anaphylaxis can be increased when Fosinopril is combined with Patent Blue. Approved Penbutolol Fosinopril may increase the hypotensive activities of Penbutolol. Approved, Investigational Penicillin G Acyl-Serine The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Penicillin G Acyl-Serine. Experimental Pentamidine The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Pentamidine. Approved, Investigational Pentobarbital Pentobarbital may increase the hypotensive activities of Fosinopril. Approved, Investigational, Vet Approved Pentolinium Fosinopril may increase the hypotensive activities of Pentolinium. Approved Perindopril Fosinopril may increase the hypotensive activities of Perindopril. Approved Perindoprilat Fosinopril may increase the hypotensive activities of Perindoprilat. Experimental Phalaris arundinacea pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Phalaris arundinacea pollen. Approved Phalaris minor pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Phalaris minor pollen. Approved Phenelzine Phenelzine may increase the hypotensive activities of Fosinopril. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Fosinopril. Withdrawn Phenobarbital Phenobarbital may increase the hypotensive activities of Fosinopril. Approved, Investigational Phenoxybenzamine Fosinopril may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Fosinopril. Withdrawn Phentolamine Fosinopril may increase the hypotensive activities of Phentolamine. Approved Phenyl aminosalicylate The risk or severity of renal failure can be increased when Phenyl aminosalicylate is combined with Fosinopril. Approved Phenylbutazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Fosinopril. Approved, Vet Approved Phleum pratense pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Phleum pratense pollen. Approved, Investigational Pinacidil Pinacidil may increase the hypotensive activities of Fosinopril. Approved Pindolol Fosinopril may increase the hypotensive activities of Pindolol. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Pipamperone is combined with Fosinopril. Approved, Investigational Piretanide Piretanide may increase the hypotensive activities of Fosinopril. Approved Pirlindole Pirlindole may increase the hypotensive activities of Fosinopril. Approved Piroxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Fosinopril. Approved, Investigational Pirprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Pirprofen is combined with Fosinopril. Experimental Pivhydrazine Pivhydrazine may increase the hypotensive activities of Fosinopril. Withdrawn Poa annua pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Poa annua pollen. Approved Poa compressa pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Poa compressa pollen. Approved Poa pratensis pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Poa pratensis pollen. Approved Polythiazide The risk or severity of hypotension can be increased when Polythiazide is combined with Fosinopril. Approved Potassium acetate The risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Fosinopril. Approved, Investigational Potassium bicarbonate The risk or severity of hyperkalemia can be increased when Potassium bicarbonate is combined with Fosinopril. Approved Potassium cation The risk or severity of hyperkalemia can be increased when Potassium cation is combined with Fosinopril. Approved, Investigational Potassium Chloride The risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Fosinopril. Approved, Withdrawn Potassium Citrate The risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Fosinopril. Approved, Investigational, Vet Approved Practolol Fosinopril may increase the hypotensive activities of Practolol. Approved Pramipexole The risk or severity of adverse effects can be increased when Pramipexole is combined with Fosinopril. Approved, Investigational Pranoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Pranoprofen is combined with Fosinopril. Experimental, Investigational Prazosin Prazosin may increase the hypotensive activities of Fosinopril. Approved Pregabalin The risk or severity of angioedema can be increased when Fosinopril is combined with Pregabalin. Approved, Illicit, Investigational Primidone Primidone may increase the hypotensive activities of Fosinopril. Approved, Vet Approved Proglumetacin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proglumetacin is combined with Fosinopril. Experimental Propacetamol The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Propacetamol is combined with Fosinopril. Approved, Investigational Propafenone The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Propafenone. Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Fosinopril. Approved, Investigational, Vet Approved Propranolol Fosinopril may increase the hypotensive activities of Propranolol. Approved, Investigational Propyphenazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Propyphenazone is combined with Fosinopril. Experimental Proquazone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proquazone is combined with Fosinopril. Experimental Quetiapine The risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine. Approved Quinapril Fosinopril may increase the hypotensive activities of Quinapril. Approved, Investigational Quinaprilat Fosinopril may increase the hypotensive activities of Quinaprilat. Experimental Quinethazone The risk or severity of hypotension can be increased when Quinethazone is combined with Fosinopril. Approved Quinine Quinine may increase the hypotensive activities of Fosinopril. Approved Rabeprazole Rabeprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Ramipril Ramipril may increase the hypotensive activities of Fosinopril. Approved Ramiprilat Fosinopril may increase the hypotensive activities of Ramiprilat. Experimental Rasagiline Rasagiline may increase the hypotensive activities of Fosinopril. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Fosinopril. Approved Remikiren Remikiren may increase the hypotensive activities of Fosinopril. Approved Rescinnamine Fosinopril may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Fosinopril. Approved, Investigational Reviparin The risk or severity of hyperkalemia can be increased when Reviparin is combined with Fosinopril. Approved, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Fosinopril. Approved, Investigational Riociguat Fosinopril may increase the hypotensive activities of Riociguat. Approved Risperidone Fosinopril may increase the hypotensive activities of Risperidone. Approved, Investigational Rituximab Fosinopril may increase the hypotensive activities of Rituximab. Approved Robenacoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Robenacoxib is combined with Fosinopril. Experimental, Vet Approved Rofecoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Fosinopril. Approved, Investigational, Withdrawn Ropinirole The risk or severity of adverse effects can be increased when Ropinirole is combined with Fosinopril. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Fosinopril. Approved Rotigotine The risk or severity of adverse effects can be increased when Rotigotine is combined with Fosinopril. Approved Sacubitril The risk or severity of angioedema can be increased when Fosinopril is combined with Sacubitril. Approved Safinamide Safinamide may increase the hypotensive activities of Fosinopril. Approved, Investigational Safrazine Safrazine may increase the hypotensive activities of Fosinopril. Withdrawn Salicylamide The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Fosinopril. Approved Salicylic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Fosinopril. Approved, Investigational, Vet Approved Salsalate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Fosinopril. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Fosinopril. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Fosinopril. Investigational Saxagliptin The risk or severity of angioedema can be increased when Saxagliptin is combined with Fosinopril. Approved SC-236 The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when SC-236 is combined with Fosinopril. Experimental, Investigational Secale cereale pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Secale cereale pollen. Approved Secobarbital Secobarbital may increase the hypotensive activities of Fosinopril. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Fosinopril. Approved, Investigational, Vet Approved Selexipag Fosinopril may increase the hypotensive activities of Selexipag. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Fosinopril. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Fosinopril. Approved, Investigational Sirolimus The risk or severity of angioedema can be increased when Sirolimus is combined with Fosinopril. Approved, Investigational Sitagliptin The risk or severity of angioedema can be increased when Sitagliptin is combined with Fosinopril. Approved, Investigational Sitaxentan Fosinopril may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium aurothiomalate The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Fosinopril is combined with Sodium aurothiomalate. Approved, Investigational Sodium bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sodium phosphate, monobasic The risk or severity of nephrotoxicity can be increased when Fosinopril is combined with Sodium phosphate, monobasic. Approved Sorghum bicolor subsp. drummondii pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Sorghum bicolor subsp. drummondii pollen. Approved Sorghum halepense pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Sorghum halepense pollen. Approved Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril. Approved Spirapril Fosinopril may increase the hypotensive activities of Spirapril. Approved Spironolactone The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fosinopril. Approved Streptokinase The risk or severity of adverse effects can be increased when Streptokinase is combined with Fosinopril. Approved, Investigational Succinylcholine The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Succinylcholine. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Fosinopril. Approved, Investigational Sulfasalazine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Fosinopril. Approved Sulindac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Fosinopril. Approved, Investigational Sulodexide The risk or severity of hyperkalemia can be increased when Sulodexide is combined with Fosinopril. Approved, Investigational Suprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Suprofen is combined with Fosinopril. Approved, Withdrawn Suxibuzone The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Suxibuzone is combined with Fosinopril. Experimental Tacrolimus The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Tacrolimus. Approved, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Fosinopril. Approved, Investigational Talinolol Fosinopril may increase the hypotensive activities of Talinolol. Investigational Talniflumate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Talniflumate is combined with Fosinopril. Approved Tamsulosin The risk or severity of adverse effects can be increased when Tamsulosin is combined with Fosinopril. Approved, Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Fosinopril. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Fosinopril. Approved, Investigational Temocapril Fosinopril may increase the hypotensive activities of Temocapril. Experimental, Investigational Temsirolimus The risk or severity of angioedema can be increased when Temsirolimus is combined with Fosinopril. Approved Teneligliptin The risk or severity of angioedema can be increased when Teneligliptin is combined with Fosinopril. Investigational Tenidap The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenidap is combined with Fosinopril. Experimental Tenoxicam The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Fosinopril. Approved Tepoxalin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tepoxalin is combined with Fosinopril. Vet Approved Terazosin Fosinopril may increase the hypotensive activities of Terazosin. Approved Tertatolol The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Tertatolol. Experimental Tetrahydropalmatine Fosinopril may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Fosinopril. Approved, Investigational, Withdrawn Theophylline Theophylline may increase the antihypertensive activities of Fosinopril. Approved Thiamylal Thiamylal may increase the hypotensive activities of Fosinopril. Approved, Vet Approved Thiopental Thiopental may increase the hypotensive activities of Fosinopril. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Fosinopril. Approved, Withdrawn Tiaprofenic acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Fosinopril. Approved Ticrynafen Fosinopril may increase the hypotensive activities of Ticrynafen. Withdrawn Timolol Fosinopril may increase the hypotensive activities of Timolol. Approved Tinoridine The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tinoridine is combined with Fosinopril. Investigational Tinzaparin The risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Fosinopril. Approved Tizanidine The risk or severity of hypotension can be increased when Tizanidine is combined with Fosinopril. Approved, Investigational Tocopherylquinone Fosinopril may increase the hypotensive activities of Tocopherylquinone. Experimental, Investigational Tolazoline Fosinopril may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Fosinopril. Approved, Withdrawn Tolfenamic Acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Fosinopril. Approved, Investigational Tolmetin The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Fosinopril. Approved Tolonidine Fosinopril may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Fosinopril. Approved Tolvaptan Tolvaptan may increase the hyperkalemic activities of Fosinopril. Approved Torasemide Torasemide may increase the hypotensive activities of Fosinopril. Approved Trandolapril Fosinopril may increase the hypotensive activities of Trandolapril. Approved Tranylcypromine Tranylcypromine may increase the hypotensive activities of Fosinopril. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Fosinopril. Approved Treprostinil Treprostinil may increase the hypotensive activities of Fosinopril. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Fosinopril. Approved, Investigational, Nutraceutical Triamterene The risk or severity of hyperkalemia can be increased when Triamterene is combined with Fosinopril. Approved Trichlormethiazide The risk or severity of hypotension can be increased when Trichlormethiazide is combined with Fosinopril. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Fosinopril. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Fosinopril. Approved, Investigational Trimethoprim Trimethoprim may increase the hyperkalemic activities of Fosinopril. Approved, Vet Approved Trimethoprim The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Trimethoprim. Approved, Vet Approved Trolamine salicylate The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Fosinopril. Approved Udenafil Udenafil may increase the antihypertensive activities of Fosinopril. Approved, Investigational Unoprostone Fosinopril may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Fosinopril. Investigational Urochloa mutica pollen The risk or severity of adverse effects can be increased when Fosinopril is combined with Urochloa mutica pollen. Approved Valdecoxib The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Fosinopril. Approved, Investigational, Withdrawn Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Fosinopril. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Fosinopril. Approved Verapamil The risk or severity of adverse effects can be increased when Fosinopril is combined with Verapamil. Approved Vildagliptin The risk or severity of angioedema can be increased when Vildagliptin is combined with Fosinopril. Approved, Investigational Vincamine Fosinopril may increase the hypotensive activities of Vincamine. Experimental Xipamide Fosinopril may increase the hypotensive activities of Xipamide. Experimental Yohimbine Yohimbine may decrease the antihypertensive activities of Fosinopril. Approved, Investigational, Vet Approved Zaltoprofen The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zaltoprofen is combined with Fosinopril. Approved, Investigational Zofenopril Fosinopril may increase the hypotensive activities of Zofenopril. Experimental Zomepirac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zomepirac is combined with Fosinopril. Withdrawn - Food Interactions
- Do not take calcium, aluminum, magnesium or iron supplements, or antacids within 2 hours of taking this medication.
- Fosinopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
- Herbs that may attenuate the antihypertensive effect of fosinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
- High salt intake may attenuate the antihypertensive effect of fosinopril.
- Take without regard to meals.
References
- Synthesis Reference
Sandra Gallego Pato, Antonio Palomo Coll, Francisco Palomo Nicolau, "Preparation of crystalline polymorphs of fosinopril sodium." U.S. Patent US20050010054, issued January 13, 2005.
US20050010054- General References
- David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. [PubMed:11854791]
- Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095]
- External Links
- Human Metabolome Database
- HMDB0014635
- KEGG Drug
- D00622
- KEGG Compound
- C07016
- PubChem Compound
- 55891
- PubChem Substance
- 46506495
- ChemSpider
- 7875352
- ChEBI
- 5163
- ChEMBL
- CHEMBL3039598
- Therapeutic Targets Database
- DAP000582
- PharmGKB
- PA449710
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Fosinopril
- ATC Codes
- C09AA09 — Fosinopril
- C09AA — ACE inhibitors, plain
- C09A — ACE INHIBITORS, PLAIN
- C09 — AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C — CARDIOVASCULAR SYSTEM
- AHFS Codes
- 24:32.04 — Angiotensin-converting Enzyme Inhibitors
- FDA label
- Download (206 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Prevention Cardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension) 1 2 Completed Treatment Diabetic Nephropathies 1 3 Completed Prevention Cardiovascular Disease (CVD) / Kidney Diseases / Microalbuminuria 1 4 Completed Treatment Chronic Obstructive Pulmonary Disease (COPD) 1 4 Completed Treatment High Blood Pressure (Hypertension) / Induction of intra-operative hypotension 1 4 Not Yet Recruiting Treatment Chronic Kidney Disease (CKD) 1 Not Available Completed Not Available Healthy Volunteers 4 Not Available Completed Treatment Diabetes Mellitus (DM) / Hypertension,Essential 1 Not Available Unknown Status Treatment Angiotensin II Type 1 Receptor Blockers / Angiotensin-Converting Enzyme Inhibitors / Kidney Insufficiency, Chronic / Proteinuria 1
Pharmacoeconomics
- Manufacturers
- Apotex inc etobicoke site
- Invagen pharmaceuticals inc
- Ranbaxy laboratories ltd
- Sandoz inc
- Teva pharmaceuticals usa inc
- Watson laboratories inc
- Watson laboratories inc florida
- Bristol myers squibb co pharmaceutical research institute
- Packagers
- Apotex Inc.
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Blu Pharmaceuticals LLC
- Bristol-Myers Squibb Co.
- Cobalt Pharmaceuticals Inc.
- Deca Pharmaceuticals LLC
- Direct Dispensing Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Eon Labs
- Glenmark Generics Ltd.
- InvaGen Pharmaceuticals Inc.
- Ivax Pharmaceuticals
- Kaiser Foundation Hospital
- Murfreesboro Pharmaceutical Nursing Supply
- Neuman Distributors Inc.
- Nucare Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Princeton Pharmaceutical Products Inc.
- Ranbaxy Laboratories
- Resource Optimization and Innovation LLC
- Teva Pharmaceutical Industries Ltd.
- Va Cmop Dallas
- Watson Pharmaceuticals
- Dosage forms
Form Route Strength Tablet Oral 10 1/1 Tablet Oral 10 mg/1 Tablet Oral 20 mg/1 Tablet Oral 40 mg/1 Tablet Oral 40 1/1 Tablet Oral Tablet Oral 10 mg Tablet Oral 20 mg - Prices
Unit description Cost Unit Monopril HCT 10-12.5 mg tablet 1.71USD tablet Monopril 10 mg tablet 1.68USD tablet Monopril 40 mg tablet 1.67USD tablet Monopril 20 mg tablet 1.62USD tablet Fosinopril Sodium-HCTZ 10-12.5 mg tablet 1.61USD tablet Fosinopril Sodium-HCTZ 20-12.5 mg tablet 1.61USD tablet Fosinopril sodium 20 mg tablet 1.25USD tablet Fosinopril sodium 40 mg tablet 1.25USD tablet Fosinopril sodium 10 mg tablet 1.21USD tablet Monopril 20 mg Tablet 1.1USD tablet Monopril 10 mg Tablet 0.91USD tablet Apo-Fosinopril 20 mg Tablet 0.61USD tablet Fosinopril 20 mg Tablet 0.61USD tablet Jamp-Fosinopril 20 mg Tablet 0.61USD tablet Mylan-Fosinopril 20 mg Tablet 0.61USD tablet Novo-Fosinopril 20 mg Tablet 0.61USD tablet Ran-Fosinopril 20 mg Tablet 0.61USD tablet Apo-Fosinopril 10 mg Tablet 0.51USD tablet Fosinopril 10 mg Tablet 0.51USD tablet Jamp-Fosinopril 10 mg Tablet 0.51USD tablet Mylan-Fosinopril 10 mg Tablet 0.51USD tablet Novo-Fosinopril 10 mg Tablet 0.51USD tablet Ran-Fosinopril 10 mg Tablet 0.51USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5006344 No 1993-01-10 2010-01-10 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 149-153 °C Not Available water solubility Insoluble Not Available logP 6.3 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00101 mg/mL ALOGPS logP 4.71 ALOGPS logP 5.62 ChemAxon logS -5.8 ALOGPS pKa (Strongest Acidic) 3.87 ChemAxon pKa (Strongest Basic) -4.4 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 110.21 Å2 ChemAxon Rotatable Bond Count 15 ChemAxon Refractivity 149.12 m3·mol-1 ChemAxon Polarizability 61.83 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9532 Blood Brain Barrier - 0.667 Caco-2 permeable - 0.6561 P-glycoprotein substrate Substrate 0.6165 P-glycoprotein inhibitor I Inhibitor 0.7161 P-glycoprotein inhibitor II Non-inhibitor 0.6774 Renal organic cation transporter Non-inhibitor 0.812 CYP450 2C9 substrate Non-substrate 0.7028 CYP450 2D6 substrate Non-substrate 0.8128 CYP450 3A4 substrate Substrate 0.6729 CYP450 1A2 substrate Non-inhibitor 0.8913 CYP450 2C9 inhibitor Non-inhibitor 0.7438 CYP450 2D6 inhibitor Non-inhibitor 0.9004 CYP450 2C19 inhibitor Non-inhibitor 0.5725 CYP450 3A4 inhibitor Non-inhibitor 0.7303 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6376 Ames test Non AMES toxic 0.7141 Carcinogenicity Non-carcinogens 0.8025 Biodegradation Not ready biodegradable 0.8102 Rat acute toxicity 2.8211 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9534 hERG inhibition (predictor II) Non-inhibitor 0.5918
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Zinc ion binding
- Specific Function
- Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
- Gene Name
- ACE
- Uniprot ID
- P12821
- Uniprot Name
- Angiotensin-converting enzyme
- Molecular Weight
- 149713.675 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Ondetti MA: Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation. 1988 Jun;77(6 Pt 2):I74-8. [PubMed:2836111]
- Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016]
- Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Proton-dependent oligopeptide secondary active transmembrane transporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
- Gene Name
- SLC15A1
- Uniprot ID
- P46059
- Uniprot Name
- Solute carrier family 15 member 1
- Molecular Weight
- 78805.265 Da
References
- Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Peptide:proton symporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
- Gene Name
- SLC15A2
- Uniprot ID
- Q16348
- Uniprot Name
- Solute carrier family 15 member 2
- Molecular Weight
- 81782.77 Da
References
- Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:41